Observational studyBMC cancer2026
Chemotherapy-induced toxicities and associated factors among patients with gastrointestinal tract cancer at two tertiary care hospitals in Ethiopia: a prospective observational study.
Observational study in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastrointestinal tract (GIT) cancers are a leading cause of cancer-related death worldwide. Chemotherapy, a cornerstone of treatment, often causes toxicities that can compromise clinical outcomes. However, evidence on the prevalence and risk factors of chemotherapy-induced toxicity among GIT cancer patients in Ethiopia remains limited. Therefore, this study aimed to assess the prevalence and associated factors of chemotherapy-induced toxicity among GIT cancer patients at two Tertiary Care Hospitals in Addis Ababa, Ethiopia.
methodsA hospital-based prospective observational study was conducted among patients enrolled prior to chemotherapy initiation and followed biweekly until treatment completion. Adverse drug reactions (ADRs) were collected from patient interviews and medical records, and assessed using the Naranjo algorithm, Hartwig-Siegel scale, and National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5. Data were analyzed using descriptive statistics and logistic regression in SPSS version 26, with P < 0.05 considered statistically significant.
resultsThe mean (± SD) age of patients was 51.59 (± 11.18) years. A total of 1499 ADRs were reported, of which 47.4% (n = 710) were hematological toxicities. Based on the Naranjo scale, 54.8% of the ADRs were classified as probable, while the Hartwig-Siegel scale severity score classified 53.7% as mild ADRs. According to NCI-CTCAE v5.0 grading score, 37.1% of the ADRs were graded ≥ 3. Poor pathological grade (AOR: 4.410, 95% CI: 1.823-10.666, p = 0.001), low baseline hemoglobin (AOR: 4.456, 95% CI: 2.021-9.824, p = 0.001) and low absolute neutrophil counts (AOR: 2.237, 95% CI: 1.061-4.717, p = 0.034) were significantly associated with severe ADRs. Granulocyte colony-stimulating factor (G-CSF) use was independently associated with lower odds of high-grade ADRs (AOR = 0.508, 95% CI: 0.260-0.995, p = 0.048).
conclusionChemotherapy-induced toxicities were highly prevalent among GIT cancer patients, with a substantial proportion experiencing severe toxicities. Poor pathological grade, low baseline hemoglobin, and low absolute neutrophil count were significantly associated with high-grade toxicities, while G-CSF use was protective. These findings highlight the need for improved toxicity management and personalized treatment strategies in Ethiopian oncology practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.